As of 06 Nov 2026 13:32 UTC. Status is always as stated in the latest recorded notice; the sources do not publish resolution, so nothing on this page says a medicine is back — see methodology.
Presentations, as stated in the latest recorded notice
Each line is re-expressed from MSN/2023/108 (28 Nov 2023): the product named, the status the source stated, and the expected-back phrase kept as written. Not the source's sentence, and not an observation of stock.
| Presentation | Status, as stated | Expected back, as stated | Stated in |
|---|---|---|---|
| Flixonase Nasal Dropsaffected product · inferred from phrasing | Discontinued, as stated | — not stated for this line | notice of 28 Nov 2023 |
| Generic fluticasone 400microgram/unit dose nasal drops (Aspire Pharma)affected product · inferred from phrasing | Limited supply, as stated | early February 2024precision: early in the month · window end 10 Feb 2024, derived from “early February 2024” | notice of 28 Nov 2023 |
| Alternative steroid nasal drops and spraysclass-level statement by the source, not a named product · inferred from phrasing | Stated as available | — not stated for this line | notice of 28 Nov 2023 |
Protocol in force
No Serious Shortage Protocol matched to this name is in force on the NHSBSA register. Matching is by name until identifier coding lands.
Named in the source as remaining available
The latest recorded notice names no alternative as remaining available.
Identifiers — Fluticasone
Grouping under review The name on this page has not been matched to one BNF chemical with enough confidence to assert it; nothing here is grouped until a reviewer confirms it.
BNF chemical and SNOMED identifiers from NHSBSA Prescription Cost Analysis (Open Government Licence), matched by name (presentation name), confidence not asserted — grouping under review where marked
BNF SNOMED mapping, NHSBSA Copyright 2026; Prescription Cost Analysis (PCA) Monthly Administrative Data, NHSBSA Copyright 2026. This information is licenced under the terms of the Open Government Licence.
History
Notified short 4 times on record since 2022 — a recurring shortage spanning 1.7 years. We record when a shortage is declared, not when stock returns — the source doesn't publish that. An update sharing a reference counts as one episode.
| Issued | Notice | Kind | Tier | Reference |
|---|---|---|---|---|
| 28 Nov 2023 | Medicine Supply Notification: Fluticasone 400microgram/unit dose nasal drops | Supply notification | Tier 2 | MSN/2023/108 |
| 21 Dec 2022 | Medicine Supply Notification: Fluticasone 50microgram / Salmeterol 25microgam (Combisal® ) pressurised metered dose inhaler (pMDI) | Supply notification | Tier 2 | MSN/2022/108 |
| 03 Aug 2022 | Medicine Supply Notification: Fluticasone 125microgram / Salmeterol 25microgram (Combisal®) pressurised metered dose inhaler (pMDI) | Supply notification | Tier 2 | MSN/2022/065 |
| 07 Mar 2022 | Medicine Supply Notification: Fluticasone 50microgram / Formoterol 5microgram per dose (Flutiform® ) inhaler CFC free | Supply notification | Tier 3 | MSN/2022/019 |
Also recorded under
No other name appears in this medicine's notice titles. Grouping is by the head name in each title; brand and generic names may still sit on separate pages until identifier coding refines it — see the A–Z.
Scotland — separate record
NHS Scotland issues its own Medicine Supply Alert Notices. These match this medicine's name; they are shown beside, never added to, the England record.
- MSAN(2020)90 Fluticasone propionate (Flixotide®) 0.5mg/2ml and 2mg/2ml Nebules · issued 29 Sep 2020 · valid until Mid-February 2021, as stated · matched by name PDF ↗
- MSAN(2020)73 Fluticasone propionate (Flixotide®) 0.5mg/2ml and 2mg/2ml Nebules · issued 27 Jul 2020 · valid until Mid-December 2020, as stated · matched by name PDF ↗
- MSAN(2020)64 Fluticasone propionate (Flixotide®) 0.5mg/2ml and 2mg/2ml Nebules · issued 30 Jun 2020 · valid until 4 November 2020, as stated · matched by name PDF ↗